Empirical Vs. Susceptibility-Guided Treatment of Infection: A Systematic Review and Meta-Analysis

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2022 Jul 1

PMID 35774456

Authors

Olga P Nyssen

Marta Espada

Javier P Gisbert

Affiliations

Soon will be listed here.

Abstract

Background: Treating infection according to antibiotic resistance has been frequently recommended. However, information on its real effectiveness is scarce.

Aim: The aim of this study is to perform a meta-analysis comparing empirical vs. susceptibility-guided treatment of .

Methods: : Studies comparing empirical versus susceptibility-guided treatment were selected. : electronic and manual up to August 2021. : by intention-to-treat (random-effects model).

Results: Overall, 54 studies were included (6,705 patients in the susceptibility-guided group and 7,895 in the empirical group). eradication rate was 86 vs. 76%, respectively (RR: 1.12; 95% CI: 1.08-1.17; : 83%). Similar results were found when only RCTs were evaluated (24 studies; RR: 1.16; 95% CI: 1.11-1.22; : 71%) and when susceptibility testing was assessed by culture (RR: 1.12; 95% CI: 1.06-1.18) or PCR (RR: 1.14; 95% CI: 1.05-1.23). For first-line treatments (naïve patients; 30 studies), better efficacy results were obtained with the susceptibility-guided strategy (RR: 1.15; 95% CI: 1.11-1.20; : 79%). However, for empirical first-line quadruple regimens, in particular (both with and without bismuth, excluding the suboptimal triple therapies), not based on CYP2C19 gene polymorphism, no differences in efficacy were found compared with the susceptibility-guided group (RR: 1.04; 95% CI: 0.99-1.09); this lack of difference was confirmed in RCTs (RR: 1.05; 95% CI: 0.99-1.12). For rescue therapies (13 studies, most 2-line), similar results were demonstrated for both strategies, including all studies (RR: 1.09; 95% CI: 0.97-1.22; : 82%) and when only RCTs were considered (RR: 1.15; 95% CI: 0.97-1.36).

Conclusion: The benefit of susceptibility-guided treatment over empirical treatment of infection could not be demonstrated, either in first-line (if the most updated quadruple regimens are prescribed) or in rescue therapies.

Citing Articles

eradication for primary prevention of gastric cancer: progresses and challenges.

Liu Z, Xu H, You W, Pan K, Li W J Natl Cancer Cent. 2024; 4(4):299-310.

PMID: 39735441 PMC: 11674435. DOI: 10.1016/j.jncc.2024.06.006.

: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control.

Elbehiry A, Abalkhail A, Anajirih N, Alkhamisi F, Aldamegh M, Alramzi A Diseases. 2024; 12(12.

PMID: 39727641 PMC: 11727528. DOI: 10.3390/diseases12120311.

The use of real-world evidence to generate cost analysis of antibiotic susceptibility testing (AST) in patients with treatment failure in Thailand: A large population-based study.

Aumpan N, Gamnarai P, Wongcha-Um A, Miftahussurur M, Yamaoka Y, Vilaichone R Heliyon. 2024; 10(21):e39189.

PMID: 39512463 PMC: 11539252. DOI: 10.1016/j.heliyon.2024.e39189.

Antimicrobial Resistance and the Role of Next-Generation Sequencing.

Andrews C, Herzlinger M, Moss S Gastroenterol Hepatol (N Y). 2024; 20(8):469-476.

PMID: 39205950 PMC: 11348536.

Culture-based susceptibility-guided tailored versus empirical concomitant therapy as first-line Helicobacter pylori treatment: A randomized clinical trial.

Lee J, Min B, Gong E, Kim J, Na H, Ahn J United European Gastroenterol J. 2024; 12(7):941-950.

PMID: 38887840 PMC: 11497715. DOI: 10.1002/ueg2.12609.

References

Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A . Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther. 2000; 14(3):311-6. DOI: 10.1046/j.1365-2036.2000.00719.x. View

Lee H, Kim J, Cheung D, Kim T, Jun E, Oh J . Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis. 2013; 208(7):1123-30. DOI: 10.1093/infdis/jit287. View

Byambajav T, Bira N, Choijamts G, Davaadorj D, Gantuya B, Sarantuya T . Initial Trials With Susceptibility-Based and Empiric Anti- Therapies in Mongolia. Front Pharmacol. 2019; 10:394. PMC: 6476916. DOI: 10.3389/fphar.2019.00394. View

Gisbert J . Empirical or susceptibility-guided treatment for infection? A comprehensive review. Therap Adv Gastroenterol. 2020; 13:1756284820968736. PMC: 7675893. DOI: 10.1177/1756284820968736. View

. Technical annex: tests used to assess Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. Gut. 1997; 41 Suppl 2:S10-8. View

Liou J, Chen C, Chang C, Chen M, Fang Y, Lee J . Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2012; 68(2):450-6. DOI: 10.1093/jac/dks407. View

Kawai T, Yamagishi T, Yagi K, Kataoka M, Kawakami K, Sofuni A . Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol. 2009; 23 Suppl 2:S171-4. DOI: 10.1111/j.1440-1746.2008.05408.x. View

Chen H, Dang Y, Zhou X, Liu B, Liu S, Zhang G . Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis. Medicine (Baltimore). 2016; 95(7):e2750. PMC: 4998617. DOI: 10.1097/MD.0000000000002750. View

Nyssen O, Vaira D, Tepes B, Kupcinskas L, Bordin D, Perez-Aisa A . Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg). J Clin Gastroenterol. 2021; 56(2):e98-e108. DOI: 10.1097/MCG.0000000000001482. View

10.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

11.

Gisbert J, Gisbert J, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares J . Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther. 2007; 27(4):346-54. DOI: 10.1111/j.1365-2036.2007.03573.x. View

12.

Park C, Lee S, Park C, Koh H, Jun C, Park S . Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014; 109(10):1595-602. DOI: 10.1038/ajg.2014.222. View

13.

Wenzhen Y, Yumin L, Quanlin G, Kehu Y, Lei J, Donghai W . Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med. 2010; 49(12):1103-9. DOI: 10.2169/internalmedicine.49.3031. View

14.

Pan J, Shi Z, Lin D, Yang N, Meng F, Lin L . Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial. Front Med. 2020; 14(1):43-50. DOI: 10.1007/s11684-019-0706-8. View

15.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

16.

Gomollon F, Sicilia B, Ducons J, Sierra E, Revillo M, Ferrero M . Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther. 2000; 14(10):1335-8. DOI: 10.1046/j.1365-2036.2000.00833.x. View

17.

Bonoso Criado R, Perez Citores L, Perez Millan A, Montero Moreton A, Gonzalez de Castro E, Cabezudo Molleda L . Prospective comparative study of the treatment of Helicobacter pylori with antibiotic susceptibility testing-guided triple therapy compared to quadruple therapy with bismuth-metronidazole-tetracycline subcitrate. Rev Esp Enferm Dig. 2020; 113(8):597-601. DOI: 10.17235/reed.2020.7395/2020. View

18.

Fallone C, Chiba N, Veldhuyzen Van Zanten S, Fischbach L, Gisbert J, Hunt R . The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016; 151(1):51-69.e14. DOI: 10.1053/j.gastro.2016.04.006. View

19.

Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A . Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment Pharmacol Ther. 2001; 15(1):143. DOI: 10.1046/j.1365-2036.2001.00909.x. View

20.

Kwon Y, Jeon S, Nam S, Lee H, Park J . Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study. Helicobacter. 2019; 24(4):e12585. DOI: 10.1111/hel.12585. View